AVE 9488

Drug Profile

AVE 9488

Latest Information Update: 03 Jul 2007

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Heart failure

Most Recent Events

  • 03 Jul 2007 Discontinued - Phase-I for Congestive heart failure in USA (unspecified route)
  • 03 Jul 2007 Discontinued - Phase-I for Angina pectoris in USA (unspecified route)
  • 01 Mar 2005 Phase-I clinical trials in Angina pectoris in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top